Status
Conditions
Treatments
About
Current breast cancer treatment is based on surgery, radiation, chemotherapy and hormonotherapy. Conservative surgery or mastectomy are followed by complementary externe radiotherapy.
This adjuvant external breast radiotherapy (EBRT) is heavy, spread over more than 6 weeks with :
In addition, EBRT is responsible for many adverse effects, some of which can lead to lasting or permanent sequelae.
Many focused partial breast irradiation techniques have been developed in recent years with the objective of reducing the duration and morbidity of overall breast irradiation.
Among these techniques, intraoperative breast radiotherapy (IBRT) is recommended in cancers diagnosed at early stages for which tumorectomy is expected and which present a low risk of recurrence.
The main advantages of IBRTare :
RIOP SEIN is a project supported by Institut National du Cancer (INCa)
, which consists of a medico-economic evaluation of IBRT, with Intrabeam® system on surgical resection bed relative to conventional surgery + EBRT in postmenopausal patients operated by conservative surgery for Low risk breast cancer
Full description
Main objective is the economic comparison Intrabeam® system versus EBRT, in terms of real costs. Costs will be taken into account:
of equipment, of staff, of transport.
Secondary objectives are :
Compare local-regional survival without recurrence with conventional irradiation Analyze the rate of early and late complications Impact of intraoperative irradiation on the esthetic outcome and quality of life of patients
Schedule of the visits :
RIOP arm : Surgery with Intrabeam®. A first visit will be scheduled at 2 months from surgery then at 6 months then every 6 months for 5 years, then every year after 5 years.
RTE arm: surgery, EBRT over 33 sessions then visit at 6 months then every 6 months 6 for 5 years, then every year after 5 years.
In RIOP ARM, additional EBRT may be performed +/- chemotherapy if the treatment received is insufficient.
Quality of life will be assessed in each treatment arm at inclusion before randomization, 2 months after surgery, every 6 months for 5 years and every year after 5 years using quality of life questionnaires: Euroqol EQ 5D, European Organisation for Research and Treatment of Cancer (EORTC)-QlQ-C30 and BR23 module specific for breast cancer.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
246 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal